Abstract
Between 1994 and 1996 we detected 28 out of 7054 (0.4%) clinical isolates of Escherichia coli with abnormal or reduced inhibition diameters to co-amoxiclav and ceftazidime in a disc diffusion test. The increased MIC of ceftazidime (1-32 mg/L) and the effect of synergy between this antibiotic and co-amoxiclav according to the disc diffusion test suggest the presence of an extended-spectrum beta-lactamase. However, enzymatic characterization and the nucleotide sequence confirm the hyperproduction of the SHV-1 enzyme.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amoxicillin-Potassium Clavulanate Combination / pharmacology*
-
Ceftazidime / pharmacology*
-
DNA, Bacterial / analysis
-
Drug Therapy, Combination / pharmacology*
-
Electrophoresis, Gel, Pulsed-Field
-
Escherichia coli / drug effects*
-
Escherichia coli / enzymology
-
Escherichia coli / isolation & purification
-
Humans
-
Isoelectric Focusing
-
Microbial Sensitivity Tests
-
Polymerase Chain Reaction
-
Serotyping
-
Spain
-
beta-Lactamases / biosynthesis*
Substances
-
DNA, Bacterial
-
Amoxicillin-Potassium Clavulanate Combination
-
Ceftazidime
-
beta-lactamase PIT-2
-
beta-Lactamases